ALLR (Allarity Therapeutics) Total Tax Payable: $0.08 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALLR Allarity Therapeutics Inc ALLR
26 GF Score
Price $1.18
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics Total Tax Payable?

Allarity Therapeutics ALLR -0.85% 26 Total Tax Payable is $0.08 Mil as of Mar. 2026. GuruFocus rates ALLR with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Allarity Therapeutics's Total Tax Payable for the quarter that ended in Mar. 2026 was $0.08 Mil.

Allarity Therapeutics's quarterly Total Tax Payable stayed the same from Sep. 2025 ($0.08 Mil) to Dec. 2025 ($0.08 Mil) and stayed the same from Dec. 2025 ($0.08 Mil) to Mar. 2026 ($0.08 Mil).

Allarity Therapeutics's annual Total Tax Payable increased from Dec. 2023 ($0.06 Mil) to Dec. 2024 ($0.07 Mil) and increased from Dec. 2024 ($0.07 Mil) to Dec. 2025 ($0.08 Mil).

Allarity Therapeutics Total Tax Payable Related Terms

Allarity Therapeutics Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics Total Tax Payable Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial 0.06 0.04 0.06 0.07 0.08

Allarity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.08 0.08 0.08
ALLR
26GF Score
Allarity Therapeutics Inc ALLR
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of $0.08 Mil mean?
Allarity Therapeutics (ALLR) has a Total Tax Payable of $0.08 Mil as of Mar. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Allarity Therapeutics and its competitors.
Is Allarity Therapeutics' Total Tax Payable too high?
Allarity Therapeutics' current Total Tax Payable is $0.08 Mil. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' Total Tax Payable compare to NCEL and LPCN?
Allarity Therapeutics' Total Tax Payable of $0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current Total Tax Payable is $0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current Total Tax Payable of $0.08 Mil. The current Total Tax Payable is $0.08 Mil. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current Total Tax Payable is $0.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score

Get the complete analysis for ALLR

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price